ArticleBiochemistry2025
Proteomics-Based Trapping to Study Substrates of Histone Deacetylase 6 Catalytic Domain 1.
Article in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- KDAC6 alters cell morphology and motility through positive and negative modulation of F-actin distribution.FEBS open bio · 2026Article
- Role of HDAC6 in carcinomas.Discover oncology · 2026Review
- HDAC11 Deacetylates BRAF to Regulate Kinase Activity and Cell Proliferation.ACS chemical biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Histone deacetylase 6 (HDAC6) is linked with various cellular functions, such as gene expression and protein degradation, as well as many diseases, including breast cancers and Alzheimer's disease. HDAC6 removes the acetyl group of acetyllysine from histones to regulate gene expression in the nucleus. However, with predominant localization in the cytoplasm, various cytoplasmic substrates of HDAC6 have also been identified. HDAC6 is unique among the other 11 metal-dependent HDAC family members due to the presence of two independent and active deacetylase domains. Recently, an inactive mutant of HDAC6 has been used as a trap to discover substrates of the second catalytic domain (CD2). Here, substrates of the first catalytic domain (CD1) of HDAC6 were explored using trapping mutants and proteomics analysis, with 21 putative substrates identified. Among them, the E3 ubiquitin ligase HUWE1 was validated as a novel HDAC6 substrate. Specifically, E3 ligase HUWE1 was deacetylated by HDAC6 CD1 to elevate degradation activity. HDAC6 CD1 also regulated the protein levels of E3 ligase UBR5. These studies document the interplay between protein deacetylation and degradation by HDAC6 CD1, which is consistent with a model where HDAC6 CD1-mediated deacetylation influences protein degradation via E3 ligases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.